Literature DB >> 11022400

Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder.

A Duffy1, G Turecki, P Grof, P Cavazzoni, E Grof, R Joober, B Ahrens, A Berghöfer, B Müller-Oerlinghausen, M Dvoráková, E Libigerová, M Vojtĕchovský, P Zvolský, A Nilsson, R W Licht, N A Rasmussen, M Schou, P Vestergaard, A Holzinger, C Schumann, K Thau, C Robertson, G A Rouleau, M Alda.   

Abstract

OBJECTIVE: To test for genetic linkage and association with GABAergic candidate genes in lithium-responsive bipolar disorder.
DESIGN: Polymorphisms located in genes that code for GABRA3, GABRA5 and GABRB3 subunits of the GABAA receptor were investigated using association and linkage strategies. PARTICIPANTS: A total of 138 patients with bipolar 1 disorder with a clear response to lithium prophylaxis, selected from specialized lithium clinics in Canada and Europe that are part of the International Group for the Study of Lithium-Treated Patients, and 108 psychiatrically healthy controls. Families of 24 probands were suitable for linkage analysis. OUTCOME MEASURES: The association between the candidate genes and patients with bipolar disorder versus that of controls and genetic linkage within families.
RESULTS: There was no significant association or linkage found between lithium-responsive bipolar disorder and the GABAergic candidate genes investigated.
CONCLUSIONS: This study does not support a major role for the GABAergic candidate genes tested in lithium-responsive bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11022400      PMCID: PMC1407742     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  34 in total

1.  Linkage between an X-chromosome marker (deutan color blindness) and bipolar affective illness. Occurrence in the family of a lithium carbonate-responsive schizo-affective proband.

Authors:  M Baron
Journal:  Arch Gen Psychiatry       Date:  1977-06

2.  Linkage studies with X-chromosome markers in bipolar (manic-depressive) and unipolar (depressive) illnesses.

Authors:  J Mendlewicz; J L Fleiss
Journal:  Biol Psychiatry       Date:  1974-12       Impact factor: 13.382

3.  Possible role of X-linked dominant factor in manic depressive disease.

Authors:  G Winokur; V L Tanna
Journal:  Dis Nerv Syst       Date:  1969-02

4.  Analysis of familial factors in bipolar affective illness.

Authors:  G F Johnson; M M Leeman
Journal:  Arch Gen Psychiatry       Date:  1977-09

5.  A collaborative study of genetic linkage of bipolar manic-depressive illness and red/green colorblindness. A project of the biological psychiatry collaborative program of the world health organization.

Authors:  E S Gershon; J Mendlewicz; M Gastpar; P Bech; L R Goldin; P Kielholz; O J Refaelsen; F Vartanian; W E Bunney
Journal:  Acta Psychiatr Scand       Date:  1980-04       Impact factor: 6.392

6.  X-linkage and genetic heterogeneity in bipolar-related major affective illness: reanalysis of linkage data.

Authors:  N Risch; M Baron
Journal:  Ann Hum Genet       Date:  1982-05       Impact factor: 1.670

7.  Linkage between glucose-6-phosphate dehydrogenase deficiency and manic-depressive psychosis.

Authors:  J Mendlewicz; P Linkowski; J Wilmotte
Journal:  Br J Psychiatry       Date:  1980-10       Impact factor: 9.319

8.  Sixth World Congress of Psychiatric Genetics X Chromosome Workshop.

Authors:  A D Paterson
Journal:  Am J Med Genet       Date:  1999-06-18

9.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

10.  Reduced plasma and CSF gamma-aminobutyric acid in affective illness: effect of lithium carbonate.

Authors:  W H Berrettini; J I Nurnberger; T A Hare; S Simmons-Alling; E S Gershon; R M Post
Journal:  Biol Psychiatry       Date:  1983-02       Impact factor: 13.382

View more
  9 in total

Review 1.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 2.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 3.  Pharmacogenetics of bipolar disorder.

Authors:  Hader A Mansour; Martin Alda; Vishwajit L Nimgaonkar
Journal:  Curr Psychiatry Rep       Date:  2002-04       Impact factor: 5.285

Review 4.  Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

Authors:  Gavin P Reynolds; Olga O McGowan; Caroline F Dalton
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 5.  Response to treatment in bipolar disorder.

Authors:  Cristiana Cruceanu; Martin Alda; Guy Rouleau; Gustavo Turecki
Journal:  Curr Opin Psychiatry       Date:  2011-01       Impact factor: 4.741

6.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 7.  Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications.

Authors:  Firoza Mamdani; Iris Jaitovich Groisman; Martin Alda; Gustavo Turecki
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

Review 8.  The Genetics of Response to and Side Effects of Lithium Treatment in Bipolar Disorder: Future Research Perspectives.

Authors:  Fanny Senner; Mojtaba Oraki Kohshour; Safa Abdalla; Sergi Papiol; Thomas G Schulze
Journal:  Front Pharmacol       Date:  2021-03-25       Impact factor: 5.810

9.  Investigation of gamma-aminobutyric acid (GABA) A receptors genes and migraine susceptibility.

Authors:  Francesca Fernandez; Teresa Esposito; Rod A Lea; Natalie J Colson; Alfredo Ciccodicola; Fernando Gianfrancesco; Lyn R Griffiths
Journal:  BMC Med Genet       Date:  2008-12-16       Impact factor: 2.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.